A Phase 0 Study of Autophagy Induction After Bortezomib For Myeloma

Next Previous
Trial Profile

A Phase 0 Study of Autophagy Induction After Bortezomib For Myeloma

Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions

    • Most Recent Events

    • 23 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 15 Dec 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Apr 2016, as reported by ClinicalTrials.gov.
    • 12 Oct 2014 Planned End Date changed from 1 Apr 2013 to 1 Apr 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top